Paper Details

  1. Home
  2. Paper Details

What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis.

Author: AylesHelen, BurkeRachael M, CorbettElizabeth L, HosseinipourMina C, JahnAndreas, MacPhersonPeter, RickmanHannah M, SinghVindi, WilkinsonRobert J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study examined whether starting antiretroviral therapy (ART) sooner after beginning treatment for tuberculosis improves outcomes in people newly diagnosed with both HIV and TB. The study aims to determine if starting ART within two weeks of beginning TB treatment is beneficial.
Paper Details　
Original Abstract of the Article :
HIV and tuberculosis are frequently diagnosed concurrently. In March 2021, World Health Organization recommended that antiretroviral therapy (ART) should be started within two weeks of tuberculosis treatment start, at any CD4 count. We assessed whether earlier ART improved outcomes in people with ne...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294654/

データ提供：米国国立医学図書館（NLM）

The Timing is Everything: Starting Antiretroviral Therapy for HIV and Tuberculosis

This research is like a caravan journeying through a vast desert, where the goal is to find the best time to start treatment for both HIV and tuberculosis. The researchers are trying to determine if starting antiretroviral therapy (ART) earlier or later is more beneficial for patients with both infections. This is like finding the optimal time to stop for a rest and replenish supplies on a long journey.

Early Treatment, Better Outcomes: A Timely Intervention

The researchers found that starting ART within two weeks of starting tuberculosis treatment is associated with better outcomes for patients. This is an important finding because it highlights the importance of early intervention for both infections. This is like having the caravan's leader make a strategic decision to stop and rest early, which ensures the well-being of the entire group.

A Well-Prepared Caravan: The Importance of Early Treatment

This research suggests that starting ART early in the course of HIV and tuberculosis co-infection can help to improve outcomes for patients. It's like making sure the caravan is well-stocked and prepared for the journey ahead. This is important for patient care, as it can help to improve their quality of life and reduce the risk of complications.

Dr.Camel's Conclusion

This research is a crucial reminder of the importance of timely interventions in the fight against infectious diseases. It's like ensuring a safe and successful caravan journey by making strategic decisions about when and where to stop and rest. By understanding the optimal timing for starting ART, we can help to improve the lives of patients with HIV and tuberculosis.

Date :
  1. Date Completed 2021-10-25
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

34289243

DOI: Digital Object Identifier

PMC8294654

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.